查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1608057

自體免疫疾病的 IVD 和 LDT 市場：按技術、按應用分類 - 2025-2030 年全球預測

IVD & LDT For Autoimmune Diseases Market by Technology (Clinical Chemistry, Coagulation, Hematology), Application (Addison's Disease, Alopecia Areata, Ankylosing Spondylitis) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，自體免疫疾病的IVD和LDT市值為172.7億美元，預計到2024年將達到183億美元，複合年成長率為5.22%，到2030年將達到246.8億美元。

自體免疫疾病體外診斷（IVD）和實驗室測試（LDT）市場範圍包括旨在檢測和監測自體免疫疾病的診斷工具和測試。對這些測試的需求可以解決類風濕性關節炎、狼瘡、多發性硬化症和自體免疫疾病的流行，這些疾病需要準確、及時的診斷以製定有效的治療計劃，這突顯了此類疾病的增加。這些診斷主要應用於醫院、診斷實驗室和研究機構，使臨床醫生、研究人員和患者受益。主要成長動力包括分子診斷等診斷技術的進步和個人化醫療的興起。此外，醫療保健支出的增加、易患自體免疫疾病的老年人口的增加以及對疾病早期發現的意識的提高都進一步推動了市場的成長。次世代定序(NGS) 和就地檢驗的進步體現了最新的潛在機遇，產業參與者可以利用策略聯盟和技術創新來提高檢測的準確性和可靠性。然而，嚴格的法規環境、與先進診斷測試相關的高成本以及自體免疫疾病的複雜性等挑戰可能會阻礙市場擴張。為了緩解這些挑戰，公司應該專注於創新領域，例如開發具有成本效益、快速且準確的診斷工具，發現生物標記以及整合人工智慧進行預測診斷。在技​​術快速進步的推動下，市場持續保持動態競爭，對於參與企業來說，透過持續的研發保持領先地位極為重要。透過專注於未滿足的診斷需求，特別是代表性不足的自體免疫疾病，並提高全球診斷的可及性，公司可以實現永續成長。監管環境、報銷政策和技術整合的整合正在塑造市場的性質，凸顯出不斷變化的市場格局，適合創新克服現有挑戰並利用新機會。

主要市場統計
基準年[2023] 172.7億美元
預計年份 [2024] 183億美元
預測年份 [2030] 246.8億美元
複合年成長率（%） 5.22%

市場動態：針對快速發展的自體免疫疾病 IVD 和 LDT 市場揭示的關鍵市場見解

供需的動態交互作用正在改變自體免疫疾病 IVD 和 LDT 市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 各國自體免疫疾病的增加
    • 對自體免疫疾病診斷測試的認知不斷增強
    • 醫療基礎設施的改善和醫療費用的增加
  • 市場限制因素
    • 對神經精神疾病以外的健康問題的擔憂
  • 市場機會
    • 體外診斷藥物領域的技術進展
    • 加強體外診斷 (IVD)檢測套組開發的合作
  • 市場挑戰
    • 關於體外診斷藥物和LDT的嚴格規定

波特五力：駕馭自體自體免疫疾病 IVD 與 LDT 市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解自體免疫疾病 IVD 和 LDT 市場的外部影響

外部宏觀環境因素在影響自體免疫疾病 IVD 和 LDT 市場表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解自體免疫疾病 IVD 和 LDT 市場的競爭格局

對自體免疫疾病市場 IVD 和 LDT 的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV自體免疫疾病 IVD 和 LDT 市場中的定位矩陣供應商績效評估

FPNV定位矩陣是評估自體免疫疾病IVD和LDT市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製自體免疫疾病 IVD 和 LDT 市場的成功之路

自體免疫疾病 IVD 和 LDT 市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 經濟體中自體免疫疾病的發生率上升
      • 對自體免疫疾病診斷測試的認知不斷增強
      • 醫療基礎設施的發展和醫療費用的增加
    • 抑制因素
      • 對非神經精神健康問題的擔憂
    • 機會
      • IVD領域的技術進步
      • 加強體外診斷（IVD）檢測套組開發合作
    • 任務
      • IVD和LDT嚴格監管
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章自體免疫疾病的 IVD 和 LDT 市場：依技術分類

  • 臨床化學
  • 凝固
  • 血液學
  • 免疫檢測
  • 微生物學
  • 分子診斷

第7章自體免疫疾病IVD和LDT市場：依應用分類

  • 愛迪生氏症
  • 脫髮症
  • 僵直性脊椎炎
  • 抗磷脂抗體症候群
  • 克隆氏症
  • 1型糖尿病
  • 多發性硬化症
  • 發作性睡病
  • 乾癬
  • 類風濕性關節炎
  • 全身性紅斑性狼瘡
  • 系統性硬皮症
  • 潰瘍性大腸炎
  • 葡萄膜炎

第8章美洲自體免疫疾病IVD和LDT市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章 亞太地區自體免疫疾病IVD和LDT市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲自體免疫疾病IVD和LDT市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Adaptive Biotechnologies Corporation
  • Agilent Technologies Inc.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux, Inc.
  • Corgenix, Inc.
  • Creative Biolabs Inc.
  • Diasorin SPA
  • in.vent Diagnostica GmbH
  • Johnson & Johnson Services, Inc.
  • Microbix Biosystems Inc.
  • PerkinElmer, Inc.
  • Roche Diagnostics Corporation
  • SQI Diagnostics Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-ED54C46E8807

The IVD & LDT For Autoimmune Diseases Market was valued at USD 17.27 billion in 2023, expected to reach USD 18.30 billion in 2024, and is projected to grow at a CAGR of 5.22%, to USD 24.68 billion by 2030.

The market scope for In Vitro Diagnostics (IVD) and Laboratory Developed Tests (LDT) for autoimmune diseases involves diagnostic tools and tests designed to detect and monitor autoimmune conditions. The necessity of these tests is underscored by the increasing prevalence of autoimmune disorders, which demand precise and timely diagnosis for effective treatment plans, addressing disorders like rheumatoid arthritis, lupus, and multiple sclerosis. These diagnostics are applied primarily in hospitals, diagnostic laboratories, and research institutions, serving clinicians, researchers, and patients. A key growth driver includes advancements in diagnostic technologies such as molecular diagnostics and the rise in personalized medicine. Additionally, increasing healthcare expenditure, a growing geriatric population susceptible to autoimmune conditions, and rising awareness of early disease detection further fuel market growth. Latest potential opportunities are apparent in next-generation sequencing (NGS) and point-of-care testing advancements, where industry players can leverage strategic collaborations and technological innovations to enhance test accuracy and reliability. However, challenges such as stringent regulatory environments, high costs associated with advanced diagnostic tests, and the complexity of autoimmune diseases can hinder market expansion. To mitigate these challenges, companies should focus on innovation areas such as developing cost-effective, rapid, and highly accurate diagnostic tools, biomarker discovery, and integrating artificial intelligence for predictive diagnostics. The market remains dynamic and competitive, driven by rapid technological advancements, making it crucial for market participants to stay ahead of trends through continuous research and development. By focusing on unmet diagnostic needs, particularly in under-represented autoimmune disorders, and enhancing the accessibility of diagnostics globally, businesses can achieve sustainable growth. The convergence of regulatory approvals, reimbursement policies, and technological integrations shapes the market's nature, highlighting an evolving landscape ripe for innovations that can navigate existing challenges and capitalize on emerging opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 17.27 billion
Estimated Year [2024] USD 18.30 billion
Forecast Year [2030] USD 24.68 billion
CAGR (%) 5.22%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving IVD & LDT For Autoimmune Diseases Market

The IVD & LDT For Autoimmune Diseases Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of autoimmune disorders in economies
    • Increasing awareness regarding diagnostic tests for autoimmune diseases
    • Rising development of healthcare infrastructure and growing healthcare expenditure
  • Market Restraints
    • Concerns regarding extra-neuropsychiatric health problems
  • Market Opportunities
    • Technological advancements in the field of IVD
    • Rising collaborative growth for the development of in-vitro diagnostic (IVD) test kits
  • Market Challenges
    • Stringent regulations of IVDs & LDTs

Porter's Five Forces: A Strategic Tool for Navigating the IVD & LDT For Autoimmune Diseases Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the IVD & LDT For Autoimmune Diseases Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the IVD & LDT For Autoimmune Diseases Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the IVD & LDT For Autoimmune Diseases Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the IVD & LDT For Autoimmune Diseases Market

A detailed market share analysis in the IVD & LDT For Autoimmune Diseases Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the IVD & LDT For Autoimmune Diseases Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the IVD & LDT For Autoimmune Diseases Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the IVD & LDT For Autoimmune Diseases Market

A strategic analysis of the IVD & LDT For Autoimmune Diseases Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the IVD & LDT For Autoimmune Diseases Market, highlighting leading vendors and their innovative profiles. These include Adaptive Biotechnologies Corporation, Agilent Technologies Inc., Bio-Rad Laboratories, Inc., bioMerieux, Inc., Corgenix, Inc., Creative Biolabs Inc., Diasorin S.P.A., in.vent Diagnostica GmbH, Johnson & Johnson Services, Inc., Microbix Biosystems Inc., PerkinElmer, Inc., Roche Diagnostics Corporation, SQI Diagnostics Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the IVD & LDT For Autoimmune Diseases Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Clinical Chemistry, Coagulation, Hematology, Immunoassays, Microbiology, and Molecular Diagnostics.
  • Based on Application, market is studied across Addison's Disease, Alopecia Areata, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Crohn's Disease, Diabetes Type 1, Multiple Sclerosis, Narcolepsy, Psoriasis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Ulcerative Colitis, and Uveitis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of autoimmune disorders in economies
      • 5.1.1.2. Increasing awareness regarding diagnostic tests for autoimmune diseases
      • 5.1.1.3. Rising development of healthcare infrastructure and growing healthcare expenditure
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns regarding extra-neuropsychiatric health problems
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in the field of IVD
      • 5.1.3.2. Rising collaborative growth for the development of in-vitro diagnostic (IVD) test kits
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations of IVDs & LDTs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. IVD & LDT For Autoimmune Diseases Market, by Technology

  • 6.1. Introduction
  • 6.2. Clinical Chemistry
  • 6.3. Coagulation
  • 6.4. Hematology
  • 6.5. Immunoassays
  • 6.6. Microbiology
  • 6.7. Molecular Diagnostics

7. IVD & LDT For Autoimmune Diseases Market, by Application

  • 7.1. Introduction
  • 7.2. Addison's Disease
  • 7.3. Alopecia Areata
  • 7.4. Ankylosing Spondylitis
  • 7.5. Antiphospholipid Antibody Syndrome
  • 7.6. Crohn's Disease
  • 7.7. Diabetes Type 1
  • 7.8. Multiple Sclerosis
  • 7.9. Narcolepsy
  • 7.10. Psoriasis
  • 7.11. Rheumatoid Arthritis
  • 7.12. Systemic Lupus Erythematosus
  • 7.13. Systemic Sclerosis
  • 7.14. Ulcerative Colitis
  • 7.15. Uveitis

8. Americas IVD & LDT For Autoimmune Diseases Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific IVD & LDT For Autoimmune Diseases Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa IVD & LDT For Autoimmune Diseases Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adaptive Biotechnologies Corporation
  • 2. Agilent Technologies Inc.
  • 3. Bio-Rad Laboratories, Inc.
  • 4. bioMerieux, Inc.
  • 5. Corgenix, Inc.
  • 6. Creative Biolabs Inc.
  • 7. Diasorin S.P.A.
  • 8. in.vent Diagnostica GmbH
  • 9. Johnson & Johnson Services, Inc.
  • 10. Microbix Biosystems Inc.
  • 11. PerkinElmer, Inc.
  • 12. Roche Diagnostics Corporation
  • 13. SQI Diagnostics Inc.
  • 14. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET RESEARCH PROCESS
  • FIGURE 2. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET DYNAMICS
  • TABLE 7. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COAGULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ADDISON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ALOPECIA AREATA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTIPHOSPHOLIPID ANTIBODY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIABETES TYPE 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY NARCOLEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY UVEITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. SINGAPORE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. SOUTH KOREA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. SOUTH KOREA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. TAIWAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. TAIWAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. THAILAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. THAILAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. VIETNAM IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. VIETNAM IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 73. DENMARK IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. DENMARK IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. EGYPT IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. EGYPT IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. FINLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. FINLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. FRANCE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. FRANCE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. GERMANY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. GERMANY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. ISRAEL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. ISRAEL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. ITALY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. ITALY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. NETHERLANDS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. NETHERLANDS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. NIGERIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. NIGERIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. NORWAY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. NORWAY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. POLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. POLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. QATAR IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. QATAR IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. RUSSIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. RUSSIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SAUDI ARABIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. SAUDI ARABIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SOUTH AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. SPAIN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. SPAIN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. SWEDEN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. SWEDEN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. SWITZERLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. SWITZERLAND IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. TURKEY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. TURKEY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED ARAB EMIRATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED ARAB EMIRATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED KINGDOM IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED KINGDOM IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 116. IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, FPNV POSITIONING MATRIX, 2023